ADMA BIOLOGICS, INC. ADMA Cash Flow

Adma biologics, inc. (ADMA)

CashFlow / TTM

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11	Dec'10	Sep'10
CASH FLOWS FROM OPERATING ACTIVITIES:
NET LOSS
-54,456	-48,279	-55,756	-59,453	-60,989	-65,743	-60,688	-60,755	-55,044	-43,758	-35,335	-24,463	-21,439	-19,515	-19,538	-20,309	-18,976	-17,969	0	0	0	-	-	-	-18,189	-15,527	-13,077	-13,634	-9,945	-7,301	-5,058	-1,817	-2,998	-3,981	-3,978	-3,977	0	0	0
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization
3,241	3,258	3,353	3,382	3,422	3,446	3,983	3,972	3,403	2,692	1,349	630	469	469	468	469	471	469	449	385	316	247	202	203	215	210	200	194	179	182	194	200	210	219	0	0	0	-	-
Loss on disposal of fixed assets
-207	-207	-136	-128	-122	-122	-19	-8	-5	-10	-4	-4	-4	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-0	0	0	0	-	-
Stock-based compensation
2,690	2,650	2,610	2,537	2,345	2,223	2,136	2,064	1,840	1,561	1,306	1,064	1,063	1,250	1,485	1,670	1,746	1,711	1,548	1,427	1,401	1,248	1,143	1,041	903	888	0	0	0	-	-	-	57	22	0	0	0	-	-
Gain on transfer of plasma center assets
0	-	0	0	0	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Warrant liability
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-67	-37	-23	11	74	61	44	-11	-43	-60	-57	-36	0	0	0	0	-	-	-	-	-	-
Amortization of debt discount
1,365	1,180	1,015	919	1,093	1,104	1,034	932	847	781	749	756	733	676	614	553	440	353	260	167	150	133	119	109	99	91	69	45	23	2	556	556	603	740	0	0	0	-	-
Loss on extinguishment of debt
0	-	0	0	0	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Amortization of deferred financing costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	39	71	104	119	125	121	114	108	99	74	48	23	2	0	0	0	-	-	-	-	-	-
Payment-in-kind interest
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	124	181	231	230	176	119	68	19	0	0	0	0	-	-	-	-	-	-	-	-	-	-
Amortization of license revenue
-142	-142	-142	-142	-142	-142	-142	-142	-142	-142	-142	-142	-142	-142	-165	-160	-144	-127	-87	-75	-75	-75	-75	-75	-62	-44	0	0	0	-	-	-	-	-	-	-	-	-	-
Changes in operating assets and liabilities:
Accounts receivable
5,797	2,077	3,188	1,289	-2,347	-2,487	2,626	1,504	2,817	2,862	172	1,465	-104	93	126	304	592	540	638	-281	-132	383	819	962	732	-39	-273	-16	-326	-39	-61	-133	73	0	0	0	0	-	-
Inventories
33,848	34,650	26,609	11,544	6,202	5,987	458	-903	-1,067	-589	603	744	1,259	1,574	1,786	1,756	2,108	1,737	1,378	1,340	956	39	247	197	-22	403	195	-287	-168	118	35	228	-149	-308	0	0	0	-	-
Prepaid expenses and other current assets
2,805	773	416	-3	177	540	52	22	1,160	941	801	974	1	202	214	238	131	-32	-18	4	15	-155	62	27	-53	190	33	58	222	48	89	172	349	-5	0	0	0	-	-
Deposits and other assets
151	-107	83	66	-0	208	-220	30	510	482	723	475	2	0	0	0	0	-	-	-	-	14	-710	-719	-794	-593	107	116	80	-115	0	0	0	-	0	0	0	-	-
Accounts payable
3,672	3,274	3,692	3,687	-238	-20	-3,069	-1,770	1,269	2,812	5,015	1,205	1,439	476	580	1,542	649	202	-360	-873	-1,062	-937	919	1,139	1,343	1,608	591	367	870	-244	-464	-428	-762	40	0	0	0	-	-
Accrued expenses
-361	806	720	-677	-444	406	349	-214	863	614	1,838	2,164	562	416	-124	210	8	-199	461	220	310	1,351	652	426	673	76	270	504	378	150	-28	-351	-303	5	6	2	0	0	0
Accrued interest
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	73	73	-123	-69	-109	-108	-24	-36	33	33	31	0	0	0	0	-	0	0	0	-	-
Other current and non-current liabilities
0	-	0	0	0	-	0	0	0	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred rent liability
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-30	45	47	49	51	-22	-22	-22	-22	-22	-22	-22	-22	-22	-22	-22	-25	-22	0	0	0	-	-
Net cash used in operating activities
-86,553	-76,193	-75,334	-64,247	-60,531	-62,678	-57,244	-54,440	-48,307	-37,271	-27,526	-22,470	-18,499	-18,268	-18,733	-16,723	-16,365	-15,418	-14,242	-14,035	-13,885	-14,704	-14,762	-14,522	-12,852	-10,887	-9,734	-9,563	-7,979	-6,903	-5,109	-3,059	-2,557	-1,003	-1,000	-1,003	0	0	0
CASH FLOWS FROM INVESTING ACTIVITIES:
Sales of short-term investments
-	-	-	-	-	-	-	-	-	-	0	0	0	-	0	0	0	-	-	-	0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Purchase of short-term investments
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,717	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Purchase of short-term investments
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-	-	-
Purchase of property and equipment
5,776	3,811	3,036	1,294	1,656	2,095	3,286	3,626	3,221	2,676	676	111	59	73	58	62	29	26	586	1,974	2,225	2,323	1,772	392	242	196	226	237	184	118	0	0	0	-	-	-	-	-	-
Proceeds from the sale of property and equipment
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash provided by (used in) investing activities
-5,774	-3,811	-3,036	-1,294	-1,656	-2,095	-3,286	-3,626	9,523	15,213	22,850	23,659	2,390	904	678	4,596	8,787	-1,741	-6,031	-11,591	-11,534	-4,040	-8,092	-6,705	-2,445	-3,131	-226	-237	-184	-118	-83	-56	-0	-0	0	0	0	-	-
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from Hercules note payable, net of fees
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	9,850	4,850	4,850	4,850	1,000	4,906	4,906	4,906	3,906	-1,200	-850	-300	0	0	0	0	-	-
Principal payments on note payable
0	30,000	30,000	30,000	30,000	0	15,555	17,222	18,888	20,000	4,444	2,777	1,111	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	200	400	400	400	200	0	0	0	-	-
Payment of end of term fee
0	2,760	2,760	2,760	2,760	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Payment of debt refinancing fees
0	-	0	0	0	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from issuance of note payable
40,000	72,500	72,500	72,500	45,000	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Payment of debt issuance costs
123	1,679	1,679	1,679	1,555	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	30	0	0	0	-	0	0	0	-	-	-	-	-	-	-	-	-	-
Proceeds from issuance of common stock, net of offering expenses
137,101	48,397	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	10,257	10,257	10,393	10,463	0	0	0	0	-	-	-	-	17,287	17,287	17,287	17,287	0	0	0	0	-	-
Proceeds from the exercise of stock options
82	75	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Equity issuance costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	386	99	107	475	1,338	1,266	1,230	933	0	0	0	0	-	-
Payments on finance lease obligations
30	29	29	28	23	16	-2	-5	-4	0	16	15	15	15	14	14	14	13	13	13	12	12	12	12	11	11	10	10	9	9	10	10	9	9	0	0	0	-	-
Payments of leasehold improvement loan
-	-	-	-	-	19	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Contributed capital
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	-
Net cash provided by financing activities
177,028	80,002	80,009	80,004	47,103	42,921	93,296	91,646	61,861	60,750	10,372	11,836	15,726	16,838	16,782	16,853	-61	10,401	15,500	15,579	15,466	9,795	31,425	31,443	31,495	27,632	4,620	4,613	4,245	19,470	15,827	15,869	16,715	862	0	0	0	-	-
Net (decrease) increase in cash and cash equivalents
84,701	-2	1,638	14,461	-15,085	-21,852	32,766	33,579	23,076	38,692	5,695	13,024	-382	-526	-1,271	4,727	-7,639	-6,758	-4,773	-10,047	-9,953	-8,950	8,571	10,215	16,197	13,613	-5,340	-5,188	-3,919	12,447	10,634	12,753	14,158	-141	-143	-149	0	0	0
Cash paid for interest
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,330	1,326	1,231	1,239	1,003	785	669	552	427	382	272	163	58	1	3	3	3	2	2	2	0	0	0
Conversion of notes payable and accrued interest into common stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	0	0	0	-	-
Reclassification of equity issuance costs to additional paid-in capital
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	-	0	0	0	-	-
Reclassification of equity issuance costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accrued equity issuance costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	76	163	275	55	0	0	0	-	-	-	-	69	0	0	0	-	-	-	-	-	-
Warrants issued in connection with note payable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	402	219	219	219	0	0	0	0	-	-	-	-	-	-	-	-	-	-
End of term liability in connection with note payable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	26	132	132	132	106	0	0	0	-	-	-	-	-	-
Elimination of warrant liability
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	408	0	0	0	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accrued equity issuance costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-
Stock issued to shell company
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	-	-
Income taxes
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	0	0